X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
DWN12088 (bersiporocin) is a first-in-class prolyl-tRNA synthetase inhibitor, which is being evaluated in phase 2 clinical trials for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s): DWN12088
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: DWN12088
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2024
Details:
DWN12088 is world's first PRS inhibitory anti-fibrotic agent,demonstrated excellent anti-fibrotic and pulmonary function improvement effects by co-administering DWN12088 and existing drugs in an animal model.
Lead Product(s): DWN12088
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: DWN12088
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
Details:
In this study, 72 healthy adults of various ethnical backgrounds were tested for single-ascending dose test (SAD) and multiple- ascending dose test (MAD) in Australia to evaluate safety, tolerability and pharmacokinetic properties of DWN12088.
Lead Product(s): DWN12088
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: DWN12088
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2021
Details:
Daewoong Pharmaceuticals is developing “DWN12088,” a candidate material for the world's first new oral drug for pulmonary fibrosis.
Lead Product(s): DWN12088
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
